Anti-BCMA antibodies in the future management of multiple myeloma

Maria Gavriatopoulou; Ioannis Ntanasis‐Stathopoulos; Meletios A Dimopoulos; Evangelos Terpos

doi:10.1080/14737140.2019.1586539

Abstract

1 min read

B-cell maturation antigen (BCMA) belongs to the tumor necrosis factor receptor family and is expressed on late B-cells and plasma cells. Serum BCMA is elevated in patients with multiple myeloma (MM) and chronic lymphocytic leukemia (CLL), and might represent a novel prognostic and monitoring tool. Serum BCMA levels can predict both progression free survival (PFS) and overall survival (OS). Several therapeutic strategies are currently under investigation including BCMA-directed monoclonal Abs (either naked or with drug conjugates, and bispecific Abs) and cellular T-cell therapies (chimeric antigen receptor T-cells) with impressive clinical results. Areas covered: This review aims to present the mechanisms of action and the available data on efficacy and safety of therapies targeting BCMA. Expert opinion: The preliminary preclinical and clinical results from the phase 1 and 2 studies have demonstrated significant activity of the anti-BCMA therapeutic strategies. The main toxicities induced include Cytokine Release Syndrome (CRS) and ocular toxicity. The management of these adverse events remains currently an issue of controversy.

Related publications

Article2025

Sequencing BCMA‐ and GPRC5D‐targeting immunotherapies in multiple myeloma: Practical guidance from the European Myeloma Network

Niels W.C.J. van de Donk, Philippe Moreau, Jesús F. San Miguel, María‐Victoria Mateos, Meletios A Dimopoulos, Sonja Zweegman, Francesca Gay, Monika Engelhardt, Roberto Mina, Elena Zamagni, Michel Delforge, Meral Beksaç, Andrew Spencer, Fredrik Schjesvold, Christoph Driessen, Martin Kaiser, Aurore Perrot, Ralph Wäsch, Charlotte L.B.M. Korst, Annemiek Broijl, Cyrille Touzeau, Salomon Manier, Roman Hájek, Jelena Bila, Güldane Cengiz Seval, Michael O’Dwyer, Heinz Ludwig, Carlos Fernández de Larrea, Rakesh Popat, Pellegrino Musto, Paula Rodríguez‐Otero, Kwee Yong, K. Martin Kortüm, Leo Rasche, Evangelos Terpos, Marc S. Raab, Mario Boccadoro, Pieter Sonneveld, Hermann Einsele

Article2025

Selective B-cell subset depletion underlies increased infection risk in patients with MM treated with anti-BCMA vs anti-GPRC5D bsAbs

Tomas Jelinek, David Žihala, Aintzane Zabaleta, Ioannis V. Kostopoulos, Ondřej Souček, Ondrej Venglár, Cristina Moreno, Despina Fotiou, Eva Radova, Luis‐Esteban Tamariz‐Amador, Foteini Theodorakakou, Ludmila Muroňová, Andrea Manubens, Ourania Tsitsilonis, Tereza Popková, Carmen González, Anjana Anilkumar Sithara, Francesco Corrado, Nayda Bidikian, Camila Guerrero, Veronika Kapustová, Daniel Bilek, Patrick R. Hagner,

Article2023

P822: EPIGENETIC REGULATION OF CD155 ON MULTIPLE MYELOMA CELLS INFLUENCES ANTI-TUMOR NOVEL IMMUNOTHERAPEUTIC APPROACHES

Laura Martinez‐Verbo, Lorea Villanueva, Pere Llinàs‐Arias, Carlos A. García‐Prieto, David Piñeyro, Aina Oliver‐Cáldes, Almudena García-Ortiz, Antonio Valeri, Carlos Fernández de Larrea, Joaquín Martínez‐López, Gerardo Ferrer, Manel Esteller

Article2006

BAFF and APRIL support chronic lymphocytic leukemia B-cell survival through activation of the canonical NF-κB pathway

Tomoyuki Endo, Mitsufumi Nishio, Thomas Enzler, Howard B. Cottam, Tetsuya Fukuda, Danelle F. James, Michael Karin, Thomas J. Kipps

Article2021

European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma

Benedetto Bruno, Ralph Wäsch, Monika Engelhardt, Francesca Gay, Luisa Giaccone, Mattia D’Agostino, Luis Gerardo Rodríguez‐Lobato, Sophia Danhof, Nico Gagelmann, Nicolaus Kröger, Rakesh Popat, Niels W.C.J. van de Donk, Evangelos Terpos, Meletios A Dimopoulos, Pieter Sonneveld, Hermann Einsele, Mario Boccadoro